Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

NCT02890329 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02890329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 5, 2017
Completion date
August 19, 2027
Enrollment
54 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent acute myeloid leukemia, myelodysplasia-related, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory myelodysplastic syndrome, secondary acute myeloid leukemia, secondary myelodysplastic syndrome